Company Overview of Achaogen, Inc.
Achaogen, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics/aminoglycoside antibiotics to combat multi-drug resistant (MDR) pathogens. Its products include plazomicin (ACHN-490), an aminoglycoside for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis; ACHN-975, an LpxC inhibitor for the treatment of serious infections caused by MDR gram-negative bacteria, including pan-drug resistant pseudomonas aeruginosa; and preclinical programs with differentiated activity against MDR pseudomonas aeruginosa and acinetobacter baumannii. The company’s products are used to combat against MDR gram-negative bacteria that cause system...
7000 Shoreline Court
South San Francisco, CA 94080
Founded in 2004
Key Executives for Achaogen, Inc.
Principal Scientific Founder and Advisor
Principal Entrepreneurial Founder
Vice President of Business Development
Compensation as of Fiscal Year 2013.
Achaogen, Inc. Key Developments
Achaogen, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 02:00 PM
Sep 25 13
Achaogen, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 02:00 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States. Speakers: Michael J. Eichberg, PhD, Senior Director, Alliance Management.
Achaogen, Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae
Sep 23 13
Achaogen, Inc. announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial of plazomicin in patients with serious multi-drug resistant (MDR) gram-negative bacterial infections. SPA agreement from the FDA indicates that the design and planned analyses of the clinical trial address objectives necessary to support a new drug application (NDA). This Phase 3 trial is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared with colistin in patients with bloodstream infections and nosocomial pneumonia caused by CRE. CRE are a global and growing public health concern. These bacteria are resistant to nearly all available antibiotics, including carbapenems, one of the last lines of defense against resistant infections. Mortality rates approach 50% in CRE patients with bloodstream infections, and the U.S. Centers for Disease Control and Prevention has categorized CRE as an "urgent" public health threat requiring immediate and aggressive action. Plazomicin is a next-generation aminoglycoside antibiotic that Achaogen engineered to overcome key aminoglycoside resistance mechanisms. It has potent bactericidal activity against important gram-negative pathogens, including CRE. Plazomicin is also being developed for the treatment of infections caused by certain biothreat agents, including Yersinia pestis and Francisella tularensis (which cause plague and tularemia, respectively). The development of plazomicin is supported by the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.
Achaogen, Inc. Presents at 12th Annual Needham Healthcare Conference, Apr-30-2013 09:00 AM
Apr 29 13
Achaogen, Inc. Presents at 12th Annual Needham Healthcare Conference, Apr-30-2013 09:00 AM. Venue: The Westin Grand Central Hotel, 212 East 42nd Street, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 6, 2013